ReviewRheumatology (Oxford, England)2020
Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors.
Review in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.
- Effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE): a systematic review and meta-analysis of randomized controlled trials.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Pooled it
- Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial.Signal transduction and targeted therapy · 2025Trial
- Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.Annals of the rheumatic diseases · 2022Trial
- Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies.Lupus science & medicine · 2026Article
- The microvascular footprint of lupus: nailfold capillaroscopy findings in Egyptian SLE patients and their link to disease activity, autoantibodies, and digital ischemia.Clinical rheumatology · 2026Article
- Genomic Landscape of Systemic Lupus Erythematosus and Lupus Nephritis Globally and the Gaps in Africa.International journal of molecular sciences · 2026Review
- Prevalence of falls in a pooled US cohort of adults with systemic lupus erythematosus: a nested cross-sectional study.Lupus science & medicine · 2026Article
- Article
- Anti-endothelin receptor A autoantibodies associate with immunovascular risk and activate endothelial signalling in SLE.Lupus science & medicine · 2026Article
- [Histopathological findings associated with complete clinical remission in patients with lupus nephritis].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Incidence of serious infections, herpes zoster and hepatitis B virus reactivation among patients with SLE: a cohort study using a health claims database in Japan.Lupus science & medicine · 2026Article
- Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort.Lupus science & medicine · 2026Article
- Correlation Between Systemic Inflammation Response Index and Systemic Immune-Inflammation Index and Disease Activity of Lupus Nephritis in Children.Children (Basel, Switzerland) · 2026Article
- Pulmonary diseases in SLE: a population-based cross-sectional study.Lupus science & medicine · 2026Article
- Glucocorticoid-induced diabetes mellitus: mechanisms, risk factors, and clinical pathways with insights from autoimmune rheumatic diseases.Rheumatology international · 2026Review
- Review
- Changes in attitudes toward systemic lupus erythematosus and associated factors: a retrospective cross-sectional study from China.Frontiers in immunology · 2026Observational
- Latent Profile Analysis of Symptom Severity in Systemic Lupus Erythematosus (SLE) Patients: A Cross-Sectional Study.Nursing research and practice · 2026Article
- Clinical and Psychosocial Predictors of Physical Activity in Systemic Lupus Erythematosus: A Multicentre Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- Patterns of Glomerular Injury: Histopathological Classification and Clinical Correlation.Cureus · 2025Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SLE is a chronic autoimmune rheumatic disorder of high heterogeneity in clinical presentation, treatment response and prognosis. Long-term outcomes in SLE have been dramatically improved over the past decades, however, increased morbidity and mortality, especially among young individuals, still exists. Unmet needs include residual disease activity and frequent flares, glucocorticoid treatment dependency and toxicity, comorbidity burden, reduced health-related quality of life, health disparities and damage. The main determinants of long-term outcomes in SLE are age, sex, race/ethnicity, genetic profile, environmental factors including smoking, disease activity, major organ involvement such as lupus nephritis and CNS involvement, comorbidities including cardiovascular disease and serious infections, coexistence with APS, treatment adherence, socio-economic factors and access to care. In this review we discuss trends in long-term outcomes in SLE over the years and major contributors such as genetic, disease-related, treatment, comorbidity, socio-economic and other factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.